21,609 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. acquired a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 21,609 shares of the company’s stock, valued at approximately $48,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TSHA. Bank of New York Mellon Corp purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at approximately $1,018,000. Quantum Private Wealth LLC lifted its position in Taysha Gene Therapies by 4.6% during the second quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock valued at $1,636,000 after buying an additional 32,000 shares during the period. Artal Group S.A. lifted its position in Taysha Gene Therapies by 0.7% during the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after buying an additional 24,444 shares during the period. Avoro Capital Advisors LLC boosted its holdings in shares of Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after buying an additional 14,294,445 shares in the last quarter. Finally, StemPoint Capital LP purchased a new stake in shares of Taysha Gene Therapies in the 1st quarter worth about $3,122,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Needham & Company LLC dropped their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Canaccord Genuity Group reduced their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Finally, BMO Capital Markets began coverage on Taysha Gene Therapies in a research note on Thursday, June 27th. They set an “outperform” rating and a $5.00 price objective for the company. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus price target of $6.22.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $2.17 on Tuesday. The firm has a market cap of $444.72 million, a P/E ratio of -4.43 and a beta of 0.41. Taysha Gene Therapies, Inc. has a twelve month low of $1.27 and a twelve month high of $4.32. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35. The company has a 50 day moving average of $2.22 and a 200 day moving average of $2.61.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same quarter last year, the company earned ($0.38) EPS. As a group, research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Paul B. Manning bought 1,333,333 shares of the stock in a transaction on Thursday, June 27th. The shares were acquired at an average price of $2.25 per share, for a total transaction of $2,999,999.25. Following the purchase, the insider now owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 2.70% of the stock is owned by corporate insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.